BsUFA III: Sponsors Want Formal Meetings That Don’t Require Product Analytic Data
Executive Summary
An early meeting option is needed so sponsors can discuss clinical trial endpoints and similar issues before analytic data is available, industry tells the US FDA.
You may also be interested in...
BsUFA III Talks Begin With Regulatory Science Disagreement
Brand trade group negotiators don’t support a biosimilar regulatory science proposal from the biosimilar and generic drug trade groups.
BsUFA III Talks Begin With Regulatory Science Disagreement
Brand trade group negotiators don’t support a biosimilar regulatory science proposal from the biosimilar and generic drug trade groups.
PDUFA Renewal Negotiations Nearly Complete, With CBER Slated For Major Resource Increase
While the prescription drug user fee agreement between industry and the US FDA is almost done, generic renewal talks remain ongoing, and biosimilar talks have not started.